> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lantheus To Sell Springfield Plant — PharmaLogic Will Make Its Newly Approved Treatment
- URL: https://www.bullished.co/lantheus-to-sell-springfield-plant-pharmalogic-will-make-its-newly-approved-treatment-70a2dc9b/
- Published: 2026-11-10T11:06:18.000Z
- Updated: 2026-11-10T11:06:18.000Z
- Description: Agilera will supply lutetium Lu 177 dotatate under a planned long-term agreement as Lantheus awaits its own sale to Curium.
- Author: Matteo Parrino
- Tags: SEC Filings, LNTH, Industry: Healthcare

[Lantheus Holdings](https://www.bullished.co/tag/lnth/), which makes radioactive drugs used mainly to image and track disease, agreed Sunday to [sell its manufacturing](https://www.sec.gov/Archives/edgar/data/0001521036/000119312526453913/d166239d8k.htm?ref=bullished.co) business and Springfield, New Jersey, plant to PharmaLogic. The deal separates ownership of the operation from production of a Lantheus treatment: PharmaLogic's Agilera business will make the drug under a planned long-term supply agreement, according to an SEC filing Monday.

## A Plant Sale With Continued Supply

The sale covers Lantheus' contract drug-development and manufacturing operation as well as the Springfield facility. Agilera, PharmaLogic's therapeutic contract-manufacturing business, will produce lutetium Lu 177 dotatate for Lantheus.

That treatment, marketed as BRAVNETSA, received [final FDA approval](https://www.globenewswire.com/news-release/2026/11/05/3396238/0/en/lantheus-reports-third-quarter-2026-financial-results.html?ref=bullished.co), Lantheus said in Thursday's results announcement. The planned supply arrangement keeps the company connected to the operation it has agreed to sell.

PharmaLogic said Springfield employees will [move to Agilera](https://markets.ft.com/data/announce/detail?dockey=600-202611091605PR%5FNEWS%5FUSPRX%5F%5F%5F%5FFL92623-1&ref=bullished.co) when the transaction closes.

## Curium's Pending Purchase Of Lantheus

Lantheus is also awaiting a change in its own ownership. Under an agreement signed August 3, 2026, Curium will pay [$102.50 per share](https://www.globenewswire.com/news-release/2026/11/05/3396238/0/en/lantheus-reports-third-quarter-2026-financial-results.html?ref=bullished.co) in cash, with further payments dependent on commercial milestones.

Lantheus suspended its full-year financial forecast in connection with that pending acquisition. The manufacturing sale and Curium's purchase both remain pending.

## Imaging Drugs Remain The Core Business

Lantheus' oncology products include Pylarify, an agent used in prostate-cancer PET scans. Its diagnostics portfolio includes Definity, which improves heart ultrasound images, and Neuraceq, an agent used in Alzheimer's disease PET scans.

Contract manufacturing sits within the company's Strategic Partnerships and Other Revenue group, alongside imaging software, licensing, royalties and research partnerships. The operation being sold is therefore part of a business that extends beyond Lantheus' own imaging drugs.

The Massachusetts-headquartered company sells mainly to U.S. hospitals, independent imaging centers and government facilities. It also reaches customers abroad through direct sales and third-party distributors.

Lantheus will provide transition services to PharmaLogic immediately after the manufacturing sale closes.

Learn

- [Item 8.01: other events →](https://www.bullished.co/learn/8-k-items-explained/#item-801-other-events)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Lantheus Holdings, Inc. (LNTH)](https://www.sec.gov/Archives/edgar/data/0001521036/000119312526453913/d166239d8k.htm?ref=bullished.co) — SEC EDGAR
- [PharmaLogic to Acquire Lantheus' CDMO Business and Springfield, New Jersey Manufacturing Facility – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202611091605PR%5FNEWS%5FUSPRX%5F%5F%5F%5FFL92623-1&ref=bullished.co) — Financial Times
- [Lantheus Reports Third Quarter 2026 Financial Results](https://www.globenewswire.com/news-release/2026/11/05/3396238/0/en/lantheus-reports-third-quarter-2026-financial-results.html?ref=bullished.co) — globenewswire.com

### More on Lantheus Holdings

- [Lantheus Sets Aside Its Annual Outlook As Curium Deal Awaits Antitrust Clearance](https://www.bullished.co/lantheus-sets-aside-its-annual-outlook-as-curium-deal-awaits-antitrust-clearance-dd5ebaca/)
- [Lantheus And Curium Each Get FTC Second Request, Extending Merger Review Past The Standard Waiting Period](https://www.bullished.co/lantheus-and-curium-each-get-ftc-second-request-extending-merger-review-past-the-standard-7d8fa942/)
- [Lantheus Holders Back Curium Merger With 55.5 Million Votes For, 1.6 Million Against](https://www.bullished.co/lantheus-holders-back-curium-merger-with-55-5-million-votes-for-1-6-million-against-074eab76/)

[All Lantheus Holdings (LNTH) coverage →](https://www.bullished.co/tag/lnth/)